Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation

Por Itadani, Hiraku, Mizuarai, Shinji, Kotani, Hidehito
Publicado em 2008

Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines

Por Mizuarai, Shinji, Kawagishi, Aki, Kotani, Hidehito
Publicado em 2009

Amplification of competitive telomere sequence in living animal cells induces chromatin instability

Por Mizuarai, Shinji, Nishijima, Ken-ichi, Iijima, Shinji
Publicado em 1999

Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples

Por Mizuarai, Shinji, Machida, Takumitsu, Kobayashi, Tsutomu, Komatani, Hideya, Itadani, Hiraku, Kotani, Hidehito
Publicado em 2011

3'-Ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction

Por Fukushima, Hiroto, Abe, Tetsuya, Sakamoto, Kazuki, Tsujimoto, Hiroaki, Mizuarai, Shinji, Oie, Shinji
Publicado em 2014

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Por Mizuarai Shinji, Yamanaka Kazunori, Itadani Hiraku, Arai Tsuyoshi, Nishibata Toshihide, Hirai Hiroshi, Kotani Hidehito
Publicado em 2009-06-01

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Por Mizuarai, Shinji, Yamanaka, Kazunori, Itadani, Hiraku, Arai, Tsuyoshi, Nishibata, Toshihide, Hirai, Hiroshi, Kotani, Hidehito
Publicado em 2009

Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors

Por Ikuta, Mari, Kornienko, Maria, Byrne, Noel, Reid, John C., Mizuarai, Shinji, Kotani, Hidehito, Munshi, Sanjeev K.
Publicado em 2007

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

Por Rajeshkumar, N.V., De Oliveira, Elizabeth, Ottenhof, Niki, Watters, James, Brooks, David, Demuth, Tim, Shumway, Stuart D., Mizuarai, Shinji, Hirai, Hiroshi, Maitra, Anirban, Hidalgo, Manuel
Publicado em 2011

ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells

Por Fukushima, Hiroto, Yasumoto, Makiko, Ogasawara, Sachiko, Akiba, Jun, Kitasato, Yuhei, Nakayama, Masamichi, Naito, Yoshiki, Ishida, Yusuke, Okabe, Yoshinobu, Yasunaga, Masafumi, Horiuchi, Hiroyuki, Sakamoto, Etsuko, Itadani, Hiraku, Mizuarai, Shinji, Oie, Shinji, Yano, Hirohisa
Publicado no Mol Cancer (2016)

Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer

Por Yasumoto, Makiko, Sakamoto, Etsuko, Ogasawara, Sachiko, Isobe, Taro, Kizaki, Junya, Sumi, Akiko, Kusano, Hironori, Akiba, Jun, Torimura, Takuji, Akagi, Yoshito, Itadani, Hiraku, Kobayashi, Tsutomu, Hasako, Shinichi, Kumazaki, Masafumi, Mizuarai, Shinji, Oie, Shinji, Yano, Hirohisa
Publicado no Cancer Med (2016)